NASDAQ:INSM - Insmed Stock Price, Forecast & News

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed Incorporated (NASDAQ:INSM) issued its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.01. The biopharmaceutical company earned $38.89 million during the quarter, compared to the consensus estimate of $35.89 million. Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. During the same quarter in the prior year, the business earned ($1.14) EPS. View Insmed's Earnings History.

Insmed is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insmed.

Insmed will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 equities research analysts have issued 1 year price objectives for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's stock price to reach $43.43 in the next year. This suggests a possible upside of 41.7% from the stock's current price. View Analyst Price Targets for Insmed.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

Headlines about INSM stock have trended somewhat positive on Monday, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Insmed.

Insmed saw a drop in short interest in January. As of January 31st, there was short interest totalling 12,940,000 shares, a drop of 8.6% from the January 15th total of 14,150,000 shares. Based on an average daily trading volume, of 946,400 shares, the days-to-cover ratio is presently 13.7 days. Currently, 15.3% of the shares of the company are sold short. View Insmed's Current Options Chain.

Some companies that are related to Insmed include Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Geron (GERN), Gilead Sciences (GILD), Capstone Turbine (CPST), Incyte (INCY), NVIDIA (NVDA), CHIMERA INVT CO/SH NEW (CIM), B2Gold (BTG) and Micron Technology (MU).

Insmed's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Palo Alto Investors LP (7.67%), Eagle Asset Management Inc. (1.69%), Fairmount Funds Management LLC (1.11%), Goldman Sachs Group Inc. (1.04%) and Foresite Capital Management II LLC (0.99%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Point72 Asset Management L.P., Marshall Wace LLP, Palo Alto Investors LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Rafferty Asset Management LLC and Asymmetry Capital Management L.P.. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Donald J Hayden Jr, John Goll, Orlov S Nicole Schaeffer and William Lewis. View Insider Buying and Selling for Insmed.

INSM stock was acquired by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, FMR LLC, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, California Public Employees Retirement System, Franklin Resources Inc., Raymond James & Associates and Virtus ETF Advisers LLC. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $30.64.

Insmed has a market capitalization of $2.74 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

The official website for Insmed is http://www.insmed.com/.

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]